We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

197 hedge funds and large institutions have $434M invested in PDL BioPharma, Inc. in 2016 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 60 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% more capital invested

Capital invested by funds: $397M → $434M (+$37.1M)

7% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 60

2% less call options, than puts

Call options by funds: $2.74M | Put options by funds: $2.8M

2% less funds holding

Funds holding: 201 → 197 (-4)

13% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 30

Holders
197
Holders Change
-4
Holders Change %
-1.99%
% of All Funds
5.26%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
26
Increased
64
Reduced
60
Closed
30
Calls
$2.74M
Puts
$2.8M
Net Calls
-$53K
Net Calls Change
+$1.45M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$8.35M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$6.72M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.88M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$2.35M
5
GPP
Great Point Partners
Connecticut
+$2.05M

Top Sellers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
-$6.54M
2
GAM
Gotham Asset Management
New York
-$3.26M
3
AAM
Advisors Asset Management
Colorado
-$2.78M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$2.63M
5
EA
Emerald Acquisition
Washington
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
176
Herndon Capital Management
Georgia
$6K – – –
IF
177
Ironwood Financial
Arizona
$4K – – –
Fifth Third Bancorp
178
Fifth Third Bancorp
Ohio
$4K +$3.97K +1,250 New
PIA
179
Piedmont Investment Advisors
North Carolina
$3.14K +$1.31K +413 +79%
US Bancorp
180
US Bancorp
Minnesota
$3K -$1.27K -400 -33%
CCM
181
Cribstone Capital Management
Maine
$3K – – –
IA
182
IFP Advisors
Florida
$2K -$3.26K -1,026 -65%
LWCFA
183
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$2K – – –
WCBA
184
Weaver C. Barksdale & Associates
Tennessee
$2K – – –
WA
185
WFG Advisors
Texas
$2K – – –
RFA
186
Reilly Financial Advisors
California
$2K +$1.59K +500 New
TCIM
187
TIAA CREF Investment Management
New York
$1.89K -$334K -105,120 -16%
SEI Investments
188
SEI Investments
Pennsylvania
$1K -$536 -169 -30%
ClearBridge Investments
189
ClearBridge Investments
New York
$1K – – –
DA
190
Denali Advisors
California
$1K – – –
GT
191
Glenmede Trust
Pennsylvania
$1K – – –
VCM
192
Versant Capital Management
Arizona
$1K – – –
WA
193
Winfield Associates
Ohio
$1K – – –
VOYA Investment Management
194
VOYA Investment Management
Georgia
$239 – – –
Jacobs Levy Equity Management
195
Jacobs Levy Equity Management
New Jersey
– -$2.63M -836,862 Closed
TC
196
TFS Capital
Pennsylvania
– -$1.86M -592,849 Closed
ARTA
197
A.R.T. Advisors
New York
– -$1.36M -432,031 Closed
ACM
198
Ativo Capital Management
Illinois
– -$861K -274,065 Closed
CG
199
Clinton Group
New York
– -$640K -203,669 Closed
LCM
200
Landscape Capital Management
New Jersey
– -$512K -163,100 Closed
5 6 7
8
9

PDLI Hedge Fund Activity: Q3 2016 in Review

197 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2016, worth a combined $434M — up 9.4% from $397M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of PDLI and 26 opened new positions — a net loss of 4 holders — while 60 trimmed existing stakes and 64 added.

The largest buyer was Armistice Capital, opening a new position worth an estimated $8.35M. The largest seller was Bank of New York Mellon, cutting an estimated $6.54M.

  • 197 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2016, down from 201 in Q2 2016.
  • Funds reported $434M of PDL BioPharma, Inc. stock for Q3 2016, up 9.4% quarter-over-quarter.
  • 26 funds opened new PDL BioPharma, Inc. positions in Q3 2016 and 30 closed out, a net change of -4 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2016 was Armistice Capital, an estimated $8.35M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2016 was Bank of New York Mellon, an estimated $6.54M sold.

Based on aggregated 13F filings for Q3 2016.